NZ547776A - Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein - Google Patents

Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein

Info

Publication number
NZ547776A
NZ547776A NZ547776A NZ54777603A NZ547776A NZ 547776 A NZ547776 A NZ 547776A NZ 547776 A NZ547776 A NZ 547776A NZ 54777603 A NZ54777603 A NZ 54777603A NZ 547776 A NZ547776 A NZ 547776A
Authority
NZ
New Zealand
Prior art keywords
animal
antigen
protein
self
mva
Prior art date
Application number
NZ547776A
Other languages
English (en)
Inventor
Paul Chaplin
Mark Suter
Mathias Ackermann
Marco Franchini
Sabine Vollstedt
Hans Peter Hefti
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ547776(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NZ547776A publication Critical patent/NZ547776A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ547776A 2002-04-19 2003-04-16 Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein NZ547776A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200590 2002-04-19

Publications (1)

Publication Number Publication Date
NZ547776A true NZ547776A (en) 2009-08-28

Family

ID=29225556

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ547776A NZ547776A (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein
NZ536592A NZ536592A (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for the vaccination of neonates

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ536592A NZ536592A (en) 2002-04-19 2003-04-16 Modified vaccinia virus ankara for the vaccination of neonates

Country Status (23)

Country Link
US (3) US7897156B2 (cg-RX-API-DMAC7.html)
EP (4) EP2204179A3 (cg-RX-API-DMAC7.html)
JP (4) JP4801880B2 (cg-RX-API-DMAC7.html)
KR (2) KR20110017904A (cg-RX-API-DMAC7.html)
CN (1) CN100540051C (cg-RX-API-DMAC7.html)
AT (1) ATE366586T2 (cg-RX-API-DMAC7.html)
AU (1) AU2003239805B2 (cg-RX-API-DMAC7.html)
BR (1) BR0309339A (cg-RX-API-DMAC7.html)
CA (1) CA2478009C (cg-RX-API-DMAC7.html)
CY (1) CY1106848T1 (cg-RX-API-DMAC7.html)
DE (1) DE60314823T3 (cg-RX-API-DMAC7.html)
DK (1) DK1420822T4 (cg-RX-API-DMAC7.html)
EA (1) EA011233B1 (cg-RX-API-DMAC7.html)
ES (1) ES2288609T5 (cg-RX-API-DMAC7.html)
IL (1) IL163701A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04010353A (cg-RX-API-DMAC7.html)
NO (1) NO336348B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ547776A (cg-RX-API-DMAC7.html)
PL (1) PL220781B1 (cg-RX-API-DMAC7.html)
PT (1) PT1420822E (cg-RX-API-DMAC7.html)
SG (1) SG173216A1 (cg-RX-API-DMAC7.html)
UA (1) UA85371C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003088994A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1335987E (pt) * 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
AU2003239805B2 (en) * 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
WO2004043490A1 (en) * 2002-11-07 2004-05-27 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Smallpox vaccine regimen
PT1855720T (pt) 2005-02-23 2016-12-14 Bavarian Nordic As Uso de um poxvírus modificado para a rápida indução de imunidade contra um poxvírus ou outros agentes infeciosos
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
US8883168B2 (en) 2010-11-05 2014-11-11 Bavarian Nordic A/S Modulation of immune responses by the poxviral K4 protein
CN108126204A (zh) * 2011-03-11 2018-06-08 特斯通有限责任合伙公司 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
EP3639851A1 (en) * 2012-09-04 2020-04-22 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
JP6480875B2 (ja) 2013-03-15 2019-03-13 バヴァリアン・ノルディック・アクティーゼルスカブ 単一高用量のｍｖａは、新生児及び幼児において防御免疫応答を引き起こす
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
UA113442C2 (xx) 2015-01-27 2017-01-25 Ентеросорбент
CA2977660A1 (en) * 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
JP6936153B2 (ja) 2015-04-17 2021-09-15 メモリアル スローン ケタリング キャンサー センター Ｍｖａ又はｍｖａδｅ３ｌの固形腫瘍免疫療法剤としての使用
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
AU2017222686B2 (en) 2016-02-25 2021-12-23 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
JP7480126B2 (ja) 2018-09-15 2024-05-09 メモリアル スローン ケタリング キャンサー センター がん免疫療法のための、組換えポックスウイルス
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
MX2022005980A (es) 2019-11-18 2022-09-07 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos.
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914408A (en) * 1973-10-12 1975-10-21 Univ Nebraska Vaccine for neonatal calf diarrhea
DE2714665A1 (de) 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPS6035647A (ja) † 1983-08-09 1985-02-23 Nippon Denso Co Ltd アンチスキツド制御装置
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5403582A (en) 1993-01-21 1995-04-04 Nippon Zeon Co., Ltd. Vaccine comprising fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
DE4405841C1 (de) † 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU694519B2 (en) 1994-04-29 1998-07-23 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US5756341A (en) 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5753489A (en) 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
ATE429505T1 (de) 1996-02-21 2009-05-15 Genetic Immunity Kft Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
US6869793B2 (en) † 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
WO1998017283A1 (en) * 1996-10-25 1998-04-30 The Wistar Institute Of Anatomy & Biology Method of vaccinating infants against infections
US6204250B1 (en) 1996-11-22 2001-03-20 The Mount Sinai Medical Center Of The City Of New York Immunization of infants
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB0023203D0 (en) * 2000-09-21 2000-11-01 Isis Innovation Vaccination method
WO1999007869A1 (en) 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
GB2370573A (en) 1998-11-18 2002-07-03 Oxford Biomedica Ltd Poxviral vectors
DE69924826T8 (de) 1998-11-18 2008-09-25 Oxford Biomedica (Uk) Ltd. Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
CN1291012C (zh) * 2000-03-14 2006-12-20 巴法里安诺迪克有限公司 修饰的安卡拉牛痘病毒(mva)的变株
CA2409874A1 (en) 2000-05-24 2001-11-29 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
AU2001268452B2 (en) * 2000-06-15 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
FI20030037A7 (fi) 2000-07-11 2003-03-10 Bayer Ag Parapoxvirus ovis-kantojen käyttö virusvastaisten lääkkeiden ja syövän vastaisten lääkkeiden tuottamiseksi
DE10042598A1 (de) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
PT1335987E (pt) * 2000-11-23 2006-05-31 Bavarian Nordic As Variante do virus vacina modificado ancara
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
JP4500049B2 (ja) * 2001-12-04 2010-07-14 バヴァリアン・ノルディック・アクティーゼルスカブ フラビウイルスｎｓ１サブユニットワクチン
AU2003239805B2 (en) * 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
MXPA04011194A (es) * 2002-05-16 2005-02-14 Bavarian Nordic As Virus de viruela recombinantes que expresan los genes homologos introducidos dentro del genoma viral de la viruela.
EP1664661A4 (en) * 2003-09-10 2008-02-13 Ra Brands Llc METHOD OF PRINTING COMPOSITE VENTILATED BAND
CA2545164C (en) * 2003-11-12 2016-11-29 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Recombinant vectors expressing mucin and carcinoembryoinic antigen
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
EP1925318A1 (en) 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8613936B2 (en) * 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements

Also Published As

Publication number Publication date
DE60314823D1 (de) 2007-08-23
EP1839672A2 (en) 2007-10-03
IL163701A0 (en) 2005-12-18
CN1646158A (zh) 2005-07-27
US7897156B2 (en) 2011-03-01
EA011233B1 (ru) 2009-02-27
US20090104224A1 (en) 2009-04-23
SG173216A1 (en) 2011-08-29
PL371594A1 (en) 2005-06-27
US20110135683A1 (en) 2011-06-09
ATE366586T2 (de) 2007-08-15
DK1420822T3 (da) 2007-10-08
KR101028937B1 (ko) 2011-04-12
EP1420822B1 (en) 2007-07-11
EP2204180A2 (en) 2010-07-07
HK1078777A1 (zh) 2006-03-24
AU2003239805A1 (en) 2003-11-03
ES2288609T5 (es) 2017-11-13
UA85371C2 (ru) 2009-01-26
EP1839672A3 (en) 2007-11-21
CA2478009C (en) 2019-03-26
EP1420822B2 (en) 2017-07-05
ES2288609T3 (es) 2008-01-16
JP5690214B2 (ja) 2015-03-25
NZ536592A (en) 2007-01-26
PL220781B1 (pl) 2016-01-29
JP2011157400A (ja) 2011-08-18
EP2204179A3 (en) 2010-12-22
NO20044941L (no) 2004-11-12
NO336348B1 (no) 2015-08-03
CN100540051C (zh) 2009-09-16
DE60314823T2 (de) 2008-03-13
CA2478009A1 (en) 2003-10-30
EP2204179A2 (en) 2010-07-07
KR20110017904A (ko) 2011-02-22
US20120183574A1 (en) 2012-07-19
MXPA04010353A (es) 2005-03-07
JP4801880B2 (ja) 2011-10-26
DE60314823T3 (de) 2017-11-16
US8163293B2 (en) 2012-04-24
JP2015061876A (ja) 2015-04-02
EP2204180A3 (en) 2010-12-22
CY1106848T1 (el) 2012-05-23
DK1420822T4 (en) 2017-10-09
AU2003239805B2 (en) 2009-09-10
WO2003088994A3 (en) 2004-02-19
JP2010120955A (ja) 2010-06-03
KR20040111467A (ko) 2004-12-31
PT1420822E (pt) 2007-09-04
WO2003088994A2 (en) 2003-10-30
EP1420822A2 (en) 2004-05-26
BR0309339A (pt) 2005-03-08
EA200401405A1 (ru) 2005-04-28
JP2005523318A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
NZ547776A (en) Modified vaccinia virus ankara for protecting an animal against an antigen or self-protein
ZA9510832B (en) Variants of human papilloma virus antigens
EP0438803A3 (en) Vaccines against cancer and infectious diseases
WO2001068117A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
HUS1600010I1 (hu) Módosított Vacciniavírus Ankara variáns
PL351893A1 (en) Vaccines
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
AU2003212170A8 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
DE502004005784D1 (de) Mittel zur behandlung von infektionen mit leishmanien
CA2457804A1 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
EA200301125A1 (ru) Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
WO2005009397A3 (en) Human lymphocyte vaccine adjuvant
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2003032917A3 (en) Hookworm vaccine
RU2008128870A (ru) Иммуностимулирующие нуклеиновые кислоты
WO2002072013A8 (en) Method of treating malignancies through induction of blood immune responses
JPS5668614A (en) Abrin-containing agent for immunological enhancement
ES2172482A1 (es) Adicion de la patente es 200100402 vacuna para la proteccion de perros frente a leishmania
RU2002102522A (ru) Способ вакцинопрофилактики вирусных болезней телят

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 APR 2016 BY CPA GLOBAL

Effective date: 20130301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2017 BY CPA GLOBAL

Effective date: 20160304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2018 BY CPA GLOBAL

Effective date: 20170303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2019 BY CPA GLOBAL

Effective date: 20180301

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2020 BY CPA GLOBAL

Effective date: 20190307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2021 BY CPA GLOBAL

Effective date: 20200306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2022 BY CPA GLOBAL

Effective date: 20210304

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2023 BY CPA GLOBAL

Effective date: 20220304

EXPY Patent expired